Status:
COMPLETED
Study on the Treatment of Taurine in Children With Autism
Lead Sponsor:
Guizhou Provincial People's Hospital
Conditions:
Autism Spectrum Disorder
Eligibility:
All Genders
30-18 years
Phase:
NA
Brief Summary
In the treatment of autism spectrum disorders (ASD), medication is only an adjunct, and the main treatment modalities are education and behavioral therapy. People with autism incur huge medical and ed...
Detailed Description
Autism spectrum disorders (ASD) are the most common disabling disorders in childhood and are characterized by social difficulties, stereotyped behavior, narrow interests and paresthesia. In recent yea...
Eligibility Criteria
Inclusion
- Aged 2.5-18 years at enrollment.
- Meet the diagnosis criteria of ASD by the diagnostic and statistical manual of mental disorders(DSM-5).
Exclusion
- Rett behavioral sign, cerebral palsy, other congenital diseases, associated with other inherited metabolic behavioral signs, epilepsy.
- Children who have had an acute or chronic infectious disease in the past 3 months.
- Children with abnormal liver and kidney function, chronic pulmonary heart disease.
- Children who have taken taurine supplements or medications in the past 3 months.
- Parents or patients refuse to participate in the study.
- The investigator determines that the subject is unable to comply with the study requirements.
Key Trial Info
Start Date :
August 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT05980520
Start Date
August 18 2023
End Date
February 28 2025
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China, 550003